A Study of comparison of efficacy and safety of intravenous iron sucrose with and without erythropoietin versus blood transfusions in patients with severe iron deficiency anemia.

  • Sakul Sakul Acharya Shri Chander College of Medical Sciences and Hospital
  • Mega Lahori
  • Anil Kumar Gupta
  • Sanjay Bhat
  • Puneeta Gupta
Keywords: Iron, Anemia, Iron Sucrose, Erythropoietin, Blood Transfusion, Hemoglobin


Objective: This study was undertaken to compare the efficacy and safety of intravenous iron sucrose with and without erythropoietin versus blood transfusions in raising the hemoglobin level in patients with severe iron deficiency anemia.Study design: Sixty patients with severe iron-deficiency anemia were randomly assigned to receive intravenously iron sucrose plus recombinant human erythropoietin or iron sucrose alone thrice weekly. Target hemoglobin value was 11.0 g/dL. Efficacy measures were reticulocyte count, increase in hematocrit, and time to target hemoglobin level. Safety profile and cost of therapy was also evaluated.            Results: Both regimens were effective, but with adjuvant recombinant human erythropoietin the reticulocyte counts were higher from day 4 (P<.01), increases in hematocrit were greater from day 4 (P <.01), and the median duration of therapy was shorter, with more patients reaching the target hemoglobin earlier. The groups did not differ with respect to adverse effects during therapy. Conclusion: Adjuvant recombinant human erythropoietin safely enhanced the efficacy of iron sucrose in the treatment of severe iron-deficiency anemia but increased the cost of therapy. 

Author Biography

Sakul Sakul, Acharya Shri Chander College of Medical Sciences and Hospital
Department of Internal MedicineAssistant Professor


1. Zuckerman KS. Approach to anemias. In: Goldman L, Schafer AI editors. Goldman’s Cecil Medicine, 23rd ed. USA: Elsevier Saunders; 2007 .p.1179.

2. Adamson JW. Iron Deficiency and Other Hypoproliferative Anemias. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J editors. Harrison’s Principles of Internal Medicine, 18th ed. USA: The McGraw-Hill; 2012. p. 844.

3. World Health Organization. The World Health Report, 2002, reducing risks, promoting healthy life. Geneva, World Health Organization, 2002.

4. World Health Organization. Iron deficiency anemia: assessment, prevention, and control, a guide for programme managers. Geneva, World Health Organization, 2001 (WHO/NHD/01.3).

5. Brugnara C. Iron deficiency and
erythropoeisis: new diagnostic approaches. Clin Chem. 2003 Oct; 49(10):1573-8.

6. Provan D. Mechanisms and management of iron deficiency anemia. Br J Haematol. 1999 Apr; 105 Suppl 1:19-26.

7. Baker SJ and DeMaeyer EM. Nutritional Anemia: its understanding and control with special reference to the work of The world Health Organisation. Lancet. 1993 Jan 2; 341(8836):1-4.

8. Pritchard JA. Hemoglobin Regeneration in Severe Iron-Deficiency Anemia Response to Orally and Parenterally Administered Iron Preparations. JAMA. 1966 Feb; 195(9):717720.

9. Allen LH. Anemia and iron deficiency: effects on pregnancy outcome. Am J Clin Nutr. 2000 May; 71(5 Suppl):1280S-4S.

10. Mungen E. Iron supplementation in pregnancy. J Perinat.Med. 2003; 31:420-426.

11. Auerbach M, Witt D, Toler W. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med. 1988 May; 111(5):566-70.

12. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial. 2000 Nov-Dec; 13(6):381-4.

13. Agrawal, D, Fotedar S., Kundu S, Mourya M. Iron Sucrose infusion in Pregnancy: a comparative study. Annals Of Applied Bio-Sciences, 2014:1(1), A40-A44.

14. American Red Cross. Practice Guidelines for Blood Transfusion: A Compilation from Recent Peer-Reviewed Literature. 2nd ed. American National Red Cross 2007.

15. Wiesen AR, Hospenthal DR, Byrd JC, Glass KL, Howard RS and Diehl LF. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med. 1994 Aug 15; 121(4):278-30.

16. Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol. 2007 Mar; 78(3):183-205.

17. Phrommintikul A, Haas SJ, Elsik M & Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007 Feb 3; 369(9559):381-8.

18. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al: TREAT Investigators. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 361, 2019-2032.

19. Dicato M & Plawny L.Erythropoietin in cancer patients: pros and cons. Curr Opin Oncol. 2010 Jul; 22(4):307-11.

20. Fusté B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al.Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro. Thromb Haemost. 2002 Oct; 88(4):678-85.

21. Lundby C, Thomsen JJ, Boushel R, Koskolou M, Warberg J, Calbet JAL & Robach P. Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol. 2007 Jan 1; 578(Pt 1):309-14.

22. Weiss G, Gasche C. Pathogenesis and treatment of anemia in inflammatory bowel disease. Haematologica. 2010; 95(2):175-178. doi:10.3324/haematol.2009.017046.

23. Eschbach JW, Egrie JC. Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8; 316(2):73-8.

24. Adamson JW, Eschbach JW. Erythropoieitin for end-stage renal disease. N Engl J Med. 1998 Aug 27; 339(9):625-7.

25. Breymann C, Visca E, Huch R, Huch A. Efficacy and safety of intravenously administered iron sucrose with and without adjuvant recombinant human erythropoietin for the treatment of resistant iron-deficiency anemia during pregnancy. Am J Obstet Gynecol. 2001 Mar; 184(4):662-7.
Original Article